162 results about "Inflammatory cell infiltration" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in improving immunity and preparing products for preventing, treating and / or assisting in treating rhinitis. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can reduce the levels of MDA and NO in serum of mice and improve the activity of SOD and CAT and the content of GSH so as to relieve oxidative stress injury; inflammatory cell infiltration of nasal mucosa is reduced, and lung tissue inflammatory mediator level and inflammation-related gene expression are reduced to inhibit inflammation; th1 / Th2 immune balance is regulated, Th2 type cytokines are reduced, Th1 type cytokines are increased, and the high-dosage effect is close to that of loratadine. The strain has a treatment effect on allergic rhinitis through multiple mechanisms, and a new choice is provided for treatment of the strain.

The invention discloses a lactobacillus paracasei strain with an effect of relieving inflammatory bowel diseases and application thereof, and belongs to the technical field of microbial fermentation. The strain is Lactobacillus paracasei JGSLP08, and the preservation number of the Lactobacillus paracasei JGSLP08 is CGMCC (China General Microbiological Culture Collection Center) NO.34274. The invention further discloses a preparation method of the Lactobacillus paracasei JGSLP08. The strain has the characteristics of strong acid resistance, bile salt resistance and gastrointestinal fluid resistance, can effectively inhibit salmonella typhimurium, escherichia coli and staphylococcus aureus, and has an excellent antioxidant effect. A DSS-induced colitis mouse model shows that the lactobacillus paracasei can effectively improve the DIA score of a mouse, regulate inflammatory factors, reduce oxidative stress injury, relieve inflammatory cell infiltration and protect the integrity of mucosal epithelium, so that the inflammatory bowel disease is relieved and / or treated.

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The application discloses application of volatile oil of Citrus aurantium in preparation of a medicine for preventing and treating allergic rhinitis. The application proposes that the volatile oil of Citrus aurantium can significantly reduce the levels of mast cell factors IL-1beta and TNF-alpha, and can also significantly reduce the levels of inflammatory factors IL-13 and IL-4 in mice, reduce inflammatory cell infiltration, and reduce eosinophilic granulocyte increase and gland hyperplasia. The application proposes that the volatile oil of Citrus aurantium has great potential as a medicinal and edible raw material for treating allergic rhinitis. The application also proposes that the volatile oil of Citrus aurantium can significantly improve symptoms such as sneezing, runny nose, and nasal itching of mice caused by allergic rhinitis, and the symptoms seriously affect the life of patients.

The invention belongs to the technical field of skin disease treatment and medicine, and particularly relates to an external pharmaceutical composition for treating atopic dermatitis and a preparation method and application thereof. The medicine composition is liquid medicine composed of blumea balsamifera oil, perfoliote knotweed herb and piper cubeba extract and is specially used for treating the atopic dermatitis (AD). According to the composition, the blumea balsamifera oil is innovatively used as a main component and cooperates with the perfoliote knotweed herb and the piper cubeba extract to form an efficient treatment scheme, and the curative effect of the composition is remarkably superior to that of a traditional method for singly using the blumea balsamifera oil. Experiments prove that the composition can effectively improve the skin barrier function, regulate immune disorder, reduce the levels of serum IgE and TSLP and inflammatory factors IL-4 and IFN-gamma, and reduce inflammatory cell infiltration, so that the AD symptom is relieved, and the recurrence rate is reduced.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention belongs to the technical field of medicines, and particularly relates to application of isodan leaf emodin in preparation of an Icam1 inhibitor, related experiments of establishment of a sepsis liver injury model induced by cecum ligation puncture (CLP) show that by applying the isodan leaf emodin, the Icam1 inhibitor can be used for preparing Icam1. According to the present invention, the level of liver tissue proinflammatory factors TNF-alpha, IL-1beta and IL-6 in the liver injury caused by sepsis is reduced, the level of the anti-inflammatory factor IL-10 is increased, and the HE dyeing of the liver tissue proves that the emodin can alleviate the CLP induced inflammatory cell infiltration in the liver tissue, can protect the structural integrity of the liver tissue, and can provide the anti-inflammatory effect on the liver tissue, such that the liver injury caused by sepsis can be inhibited, and the liver injury caused by sepsis can be inhibited. The data shows that the isodan leaf emodin can relieve sepsis liver injury and reduce liver function indexes. In research, it is found for the first time that the action mechanism of the isodan-leaf emodin in relieving the sepsis liver injury is that liver function indexes and inflammatory response are relieved by inhibiting expression of a transmembrane protein intercellular adhesion molecule-1 (Icam1), and it is indicated that the isodan-leaf emodin has a good application prospect in treating sepsis-related tissue injury.

The invention discloses an intestinal microneedle anastomosis stent with an antibacterial function and a preparation method and application thereof, which can effectively and physically isolate an anastomotic stoma from intestinal contents and provide a relatively clean local environment for healing of the anastomotic stoma. The microneedle anastomotic stent is fixed at the anastomotic stoma, so that the tension at the anastomotic stoma can be further reduced, and the occurrence of anastomotic stoma leakage caused by overlarge tension is avoided; the microneedle layer on the surface of the stent can realize in-situ long-acting slow release of berberine hydrochloride (BBH) on the superficial layer of an anastomotic stoma, so that the drug utilization rate of the BBH is improved, the initial inflammation of the anastomotic stoma can be effectively reduced, and the anastomotic stoma can be regulated and controlled to be better healed. Animal experiment results prove that the implantation of the microneedle anastomosis stent can effectively reduce inflammatory cell infiltration of local tissues, reduce anastomotic stoma arrangement and regulate the anastomotic stoma to heal smoothly.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The invention discloses an application of isothunberine or a pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating asthma diseases. It is found that in an OVA-induced mouse asthma model, the isothunberine significantly reduces airway resistance excited by acetylcholine, improves inflammatory cell infiltration and airway mucus high secretion of asthma model mouse lung tissue, reduces the levels of lgE and OVA-lgE in serum and related inflammatory factors in alveolar lavage fluid, and has the effect of preventing and treating asthma. Therefore, the effect of treating asthma is achieved. Therefore, the isothunberine has the potential of preventing or treating the asthma, provides a new treatment mode for the treatment of the asthma, and has a wide application prospect.

The invention discloses an application of glucopyranose galactooligosacharide in preparation of a medicine for treating and / or preventing allergic asthma. The invention finds that the glucopyranose galactooligosaccharide can obviously relieve airway inflammatory reaction of an allergen-induced allergic asthma model, including reducing airway inflammatory factor level, improving airway hyperreactivity and reducing lung inflammatory cell infiltration, and has no abnormal influence on blood routine and main organ functions; the composition has the advantages of small drug application dosage, low pharmaceutical cost, high safety, remarkable drug effect and the like, and has a wide application prospect.

The invention discloses application of KLF14 agonist perhexiline in preparation of a medicine for treating acute lung injury, and belongs to the technical field of biological medicine. The high expression of the KLF14 in the acute lung injury model lung is systematically clarified. KLF14 is inhibited by adopting adenovirus knock-down, and it is found that KLF14 deletion can aggravate acute lung injury induced by lipopolysaccharide by mediating release of neutrophil NETosis and inflammatory factors. The activation of the perhexiline on the KLF14 can effectively inhibit the release of neutrophil NETosis and inflammatory factors, so that the lung morphological change caused by lipopolysaccharide can be inhibited in vivo, the lung interstitial inflammatory cell infiltration is weakened, and the effect of relieving the acute lung injury is achieved. The invention provides an application of perhexiline as a KLF14 agonist in relieving acute lung injury, and provides a new therapeutic target and therapeutic drug for prevention and treatment of acute lung injury.

The invention discloses application of guaiacol in treatment of rheumatoid arthritis, and particularly relates to application of guaiacol in preparation of drugs for treating rheumatoid arthritis. Cell experiments prove that guaiacol can effectively down-regulate expression of proinflammatory factors in macrophages and up-regulate expression of anti-inflammatory factors, and has remarkable anti-inflammatory activity; animal experiments show that the guaiacol effectively relieves rheumatoid arthritis model mouse diseases, and the specific manifestation is that the guaiacol obviously relieves the mouse claw swelling degree, reduces the arthritis disease score, obviously improves joint inflammatory cell infiltration, repairs cartilage injury, inhibits osteoclast generation and reduces the number of joint apoptotic cells; meanwhile, the level of proinflammatory factors in serum of mice can be effectively reduced, and the level of proinflammatory repair factors can be up-regulated. The invention proves that guaiacol has a definite curative effect on rheumatoid arthritis, good biological safety and no obvious side effect, provides a new effective active component for the treatment of rheumatoid arthritis, and has a good prospect of being developed into the medicine for treating rheumatoid arthritis.

The application discloses application of a heteroterpene compound I in preparation of a heart failure resisting drug. The heteroterpene compound I is obtained by separation and purification from a marine fungus Aspergillus terreus GZU-311, and is used to treat a mouse heart failure model induced by adriamycin or left anterior descending coronary artery ligation, and it is found that the heteroterpene compound I can improve the heart function of the mouse, reduce myocardial cell damage, inhibit myocardial connective tissue thickening, improve myocardial cell arrangement disorder, reduce inflammatory cell infiltration, and has an effect of resisting heart failure. Therefore, the application provides application of the heteroterpene compound I in preparation of a heart failure resisting drug. The application enriches drug source molecules that can be used for treating heart failure, and is helpful to development of an anti-heart failure drug and clinical treatment.

The application provides application of a Baoji oral liquid composition in preparation of a functional dyspepsia medicine, and relates to the technical field of medicines. The application is based on the Baoji oral liquid, and it is found that the Baoji oral liquid has a remarkable effect on treating functional dyspepsia, especially cisplatin-induced functional dyspepsia. Specifically, the Baoji oral liquid can rapidly restore body weight, significantly improve body weight gain, steadily promote food intake, significantly improve gastric emptying rate and intestinal propulsion rate, protect the gastric mucosa layer, reduce inflammatory cell infiltration, repair the mucosa layer and muscle layer, improve the expression of serum gastrin and motilin, and improve the expression level of IL-4 in the gastric tissue and reduce the expression level of IL-1beta. The Baoji oral liquid has remarkable efficacy when applied in preparation of a functional dyspepsia medicine.

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The application discloses a kind of treatment granulomatous lobular mastitis plaster and preparation method thereof, it is related to traditional Chinese medicine technical field, and its technical solution points are: rhubarb, golden poplar, radix scutellariae, sanguisorba officinalis, gardenia, turmeric, purple grass, water decoct 2 times, first time 9-11 times water amount of medicinal materials is added, decoct 1-3 hours, second time 6-9 times water amount of medicinal materials is added, decoct 1-2 hours, two water decocting liquids are combined, after filtration, concentrate and obtain ointment, carry out coating, cut according to specification and place to make it solidification and shape.The application can realize the treatment granulomatous lobular mastitis, can reduce mastitis inflammation index score and inflammatory cell infiltration degree, by reducing the expression of IL6, CD86, TYROBP, ITGAX and regulating related path, play the role of treatment granulomatous lobular mastitis.

The application is a divisional application of 2025116336025, the invention provides an application of 2, 4-dihydroxy-6-methoxyacetophenone in preparation of a medicine for treating lacrimal gland secretion dysfunction related diseases, a lacrimal gland dysfunction dry eye mouse model is constructed in the application, and liposome entrapped 2, 4-dihydroxy-6-methoxyacetophenone is adopted for intervention, so that the medicine for treating lacrimal gland secretion dysfunction related diseases is obtained. Experimental results show that the ocular surface function and structure of a model animal are remarkably improved through treatment of 2, 4-dihydroxy-6-methoxyacetophenone, the cornea sodium fluorescein staining score of a mouse in a 2, 4-dihydroxy-6-methoxyacetophenone treatment group is remarkably reduced, and cornea epithelium injury is effectively repaired; the epithelial structure in the cornea tissue tends to be complete, and inflammatory cell infiltration of a matrix layer is obviously relieved; the density of goblet cells in the conjunctiva is obviously increased, which indicates that the secretion function of the mucous layer on the ocular surface is recovered. The treatment of 2, 4-dihydroxy-6-methoxyacetophenone has an improvement trend on tear film rupture time and tear secretion amount, which indicates that the 2, 4-dihydroxy-6-methoxyacetophenone has a potential effect in the aspects of maintaining tear film stability and promoting basic tear secretion.

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The application provides application of myristic ether in preparation of drugs for treating or preventing cardiovascular diseases; it is found that myristic ether has multiple protective effects on myocardial ischemia-reperfusion injury: reducing myocardial infarction area; improving myocardial contraction function; reducing myocardial interstitial edema, myocardial cell morphological change and inflammatory cell infiltration; reducing AST, CK, CKMB and LDH levels in blood; reducing myocardial cell damage and death; reducing myocardial cell LDH leakage, enhancing intracellular SOD activity; reducing myocardial cell apoptosis.

The present application relates to a new use of halogenophenol compound 4,5,2'-trihydroxy-2,5'-dibromobenzophenone, in particular in the preparation of a drug for treating inflammatory bowel disease. The halogenophenol compound of the present application can significantly alleviate the weight loss and colon shortening of the colonitis model, reduce the disease activity index of the colonitis model, reduce the inflammatory cell infiltration of the colonitis model, reduce the expression of inflammatory factors, has an immune regulation function on the intestinal tract, and is superior to the clinical first-line drug mesalazine in most indicators, and has application prospects in the treatment of inflammatory bowel disease.

The application belongs to the technical field of biological medicine, and particularly relates to application of calcium chelator BAPTA and a pharmaceutical composition. The calcium chelator BAPTA delays aging of lung fibroblasts and lung tissues by eliminating calcium accumulation in lung fibroblasts, reducing accumulation of reactive oxygen species ROS (ROS) in lung fibroblasts, DNA damage, and release of inflammatory factors. The calcium chelator BAPTA ultimately realizes the function of treating pulmonary fibrosis by inhibiting weight loss, lung tissue inflammatory cell infiltration, lung collagen deposition, and expression of fibrosis markers. The application provides a new drug source for delaying aging of lung fibroblasts and lung tissues and studying occurrence and development of pulmonary fibrosis. The drug is safe and reliable, has strong pharmacological action, small side effects, and definite curative effect.

The invention discloses a method for constructing a chronic endometritis rat model based on Hungata (preservation number: DSM 13479), and belongs to the technical field of animal models. The bacterial strain is subjected to anaerobic culture to prepare a bacterial solution, 150 mu L vagina perfusion is performed twice every 3 days for 3 weeks, rat endometrial inflammation reaction is induced, and endometrial atrophy and endometrial inflammation cell infiltration are taken as pathological characteristics. According to the invention, the problems of high infection, high death rate and the like caused by traditional injection of lipopolysaccharide or pathogenic bacteria through the uterus horn are avoided, and an efficient experimental tool is provided for mechanism research and drug development of chronic endometritis.

This invention relates to a formulation and method of application of a multicomponent mycotoxin detoxifier for poultry feed, particularly female broiler chickens, which aims to provide protection to the Bursa Fabricius due to exposure to mycotoxins in the form of aflatoxin and ochratoxin. The mycotoxin detoxifier formulation according to this invention consists of an inorganic mycotoxin binder in the form of bentonite and / or zeolite, an organic mycotoxin binder in the form of pectin and / or esterified cellulose, and a natural antioxidant in the form of vitamin E and / or antioxidant herbal extracts. The formulation is applied to poultry feed at a dose of 2 to 2.5 g per kg of feed and is able to bind aflatoxin and ochratoxin simultaneously in the digestive tract, thereby reducing the bioavailability of mycotoxins.The application of this formulation has been proven to reduce histopathological damage to the Bursa of Fabricius, including lymphoid follicle depletion, cyst formation, cell necrosis, inflammatory cell infiltration, and tissue fibrosis, while also supporting the immune system function of female broiler chickens. This invention provides an effective, efficient, and easily applicable technical solution in the poultry farming industry to address mixed mycotoxin contamination in feed.

The invention discloses an application of a Yinxiaonaotong soft capsule in preparation of a medicine for preventing and treating acute lung injury, and experimental research shows that the Yinxiaonaotong soft capsule can significantly improve lung histopathologic injury of an acute lung injury mouse model activated and induced by a complement bypass and relieve inflammatory cell infiltration. The mechanism of action is as follows: the Yindanaotong can effectively inhibit the expression of key inflammatory mediators (TNF-alpha, IL-6) and adhesion molecules (ICAM-1, P-selectin) in lung tissues and serum. Meanwhile, the medicine can down-regulate the mRNA transcriptional level of NF-kappa B p65, JNK, p38 MAPK and STAT3 signal channel related genes in lung tissues and inhibit phosphorylation activation of corresponding proteins. The results comprehensively show that the Yindan Xinnaotong compound intervenes in an inflammation signal channel through multiple targets, and plays roles in resisting inflammation and protecting lung tissues, so that the Yindan Xinnaotong compound can be used for preparing medicines for preventing and / or treating acute lung injury.

This application discloses the application of pyridostigmine in the preparation of drugs for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). Validation was conducted using animal models of NAFLD induced by three different etiologies: methionine-choline deficiency diet, high-fat diet, and leptin gene knockout. Pyridostigmine significantly improved vagal nerve activity in the model animals (e.g., improving high-frequency and baroreflex sensitivity in heart rate variability), effectively corrected serum lipid metabolism disorders (reducing LDL cholesterol), alleviated hepatocyte damage (reducing ALT and AST), and at the histopathological level, reduced hepatic steatosis, decreased inflammatory cell infiltration, and inhibited collagen deposition, thereby achieving the prevention and treatment of NAFLD.

This application proposes a traditional Chinese medicine composition and preparation method for treating atrophic gastritis of spleen deficiency and blood stasis type, involving the field of traditional Chinese medicine. It utilizes Bupleurum chinense, stir-fried Paeonia lactiflora, Citrus reticulata peel, Pinellia ternata, Codonopsis pilosula, Poria cocos, stir-fried Atractylodes macrocephala, prepared Glycyrrhiza uralensis, Agrimonia pilosa, and Curcuma zedoaria, and establishes a water extraction and decoction preparation process. A rat model of precancerous gastric lesions was established using MNNG combined with multiple factors. Normal control group, model group, folic acid group, and traditional Chinese medicine group were set up to observe the morphological and pathological changes of the gastric mucosa. The results showed that the traditional Chinese medicine composition can reduce gastric mucosal atrophy, inflammatory cell infiltration, and fibrous tissue hyperplasia, alleviate intestinal metaplasia, downregulate the expression of AKT and mTOR proteins in the gastric mucosa, and inhibit abnormal mucosal proliferation. Its effect is superior to that of folic acid, providing experimental evidence for clinical treatment.

The application discloses an intestinal micro-needle anastomosis stent with an antibacterial function and a preparation method and application thereof, which can effectively physically isolate an anastomotic stoma from intestinal contents, provides a relatively clean local environment for healing of the anastomotic stoma, and further reduces tension at the anastomotic stoma by fixing the micro-needle anastomosis stent at the anastomotic stoma, so that anastomotic leakage caused by excessive tension is avoided; a micro-needle layer on a surface of the stent can realize in-situ long-acting slow release of berberine hydrochloride (BBH) on a superficial layer of the anastomotic stoma, so that drug utilization of the BBH is improved, and occurrence of initial inflammation of the anastomotic stoma is effectively reduced, and healing of the anastomotic stoma is better regulated. Animal experiment results prove that implantation of the micro-needle anastomosis stent can effectively reduce inflammatory cell infiltration of local tissues, reduce anastomotic arrangement, and regulate smooth healing of the anastomotic stoma.